Stay updated on Pembrolizumab in Early NK/T-cell Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Early NK/T-cell Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab in Early NK/T-cell Lymphoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedThe study page now clearly indicates that it is no longer looking for participants, clarifying that recruitment has ceased. In addition, labels for the Intervention/Treatment section were updated to remove spacing around the slash and a site revision note (v3.6.0) was added.SummaryDifference0.4%

- Check21 days agoChange DetectedRevision: v3.5.5 replaces v3.5.4, signaling a page update. It reflects internal maintenance rather than changes to clinical trial details presented on the page.SummaryDifference0.1%

- Check42 days agoChange DetectedThe page revision was updated from v3.5.3 to v3.5.4, indicating a newer version of the page documentation.SummaryDifference0.1%

- Check63 days agoChange DetectedThe page’s footer revision/version indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check70 days agoChange DetectedRevision: v3.5.2 applied, replacing v3.5.0. No user-facing content or study details were altered.SummaryDifference0.1%

- Check99 days agoChange DetectedThe site revision label was updated from v3.4.3 to v3.5.0. No visible changes to study details or page content were observed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Early NK/T-cell Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Early NK/T-cell Lymphoma Clinical Trial page.